Skip to content

Released Feb 10, 2020, after the close

10-K filed Feb 27, 2020, 58 days after period end · 0001162194-20-000016

Q4 2019 · 10-K
Revenue$32.44M+0.4% vs Q4 2018+22.4% vs Q3 2019
Net Income-$12.69MderivedN/M vs Q4 2018N/M vs Q3 2019
EPS Diluted-$0.18N/M vs Q4 2018N/M vs Q3 2019
Gross Profit$17,538,000−6.8%
Operating Incomederived-$9,181,000N/M
Operating Cash Flowderived-$5,519,000N/M
Free Cash Flowderived-$6,019,000N/M
Margins · derived
Gross margin54.1%−4.1 pt vs Q4 2018
Operating margin-28.3%+6.1 pt vs Q4 2018
Net margin-39.1%+6.6 pt vs Q4 2018

What the release said

The release

Same quarter

MetricQ4 2019Q4 2018Q4 2017Q4 2016
Revenue$32.44M$32.33M$27.75M$25.08M
Net Income-$12.69M-$14.78M-$10.46M-$17.70M
EPS Diluted-$0.18-$0.36-$0.27-$0.61

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR